logo
In This Issue/Research Watch/News in Brief/News From the Iaslc Tobacco Control Committee
In Memoriam
The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study
Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer
Lung Cancer Workshop XI
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules
Diagnostic Mutation Profiling and Validation of Non–Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas
9q33.3, A Stress-Related Chromosome Region, Contributes to Reducing Lung Squamous Cell Carcinoma Risk
Overexpression of CRM1
Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC
Central versus Peripheral Tumor Location
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America
Hippo Pathway Gene Mutations in Malignant Mesothelioma
Paraneoplastic Limbic Encephalitis and Small-Cell Lung Carcinoma
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the Lung
CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
Response to Crizotinib and Clinical Outcome in ALK-Rearranged Pulmonary Pleomorphic Carcinoma
MET Mutation Associated with Responsiveness to Crizotinib
Lymph Node/Tumor SUVmax Ratio Can Predict Metastasis to Mediastinal Lymph Nodes in Lung Cancer Patients
Reply to
MET-Mutated NSCLC with Major Response to Crizotinib
Relevance of Platinum Sensitivity in Patients with Relapsed or Refractory Small-Cell Lung Cancer
Second-line Treatment of Small Cell Lung Cancer
Reply to “Diminishing Role of Platinum-Sensitivity Status in Patients with Small Cell Lung Cancer”